迪安诊断技术集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）于2024年2月6日召开 第五届董事会第四次会议审议通过了《关于回购公司股份方案的议案》，同意 使用自有资金以集中竞价交易方式回购公司人民币普通股A股股份（以下简称 "本次回购"），用于实施员工持股计划或者股权激励。回购金额不低于人民币 10,000万元（含）且不超过人民币20,000万元（含），回购价格不超过人民币 27.94元/股（含），回购期限自董事会审议通过本次回购股份方案之日起12个月 内。具体内容详见公司于2024年2月7日在巨潮资讯网披露的《关于回购公司股 份方案的公告》《回购报告书》以及公司于2024年6月12日在巨潮资讯网披露的 《关于2023年年度权益分派实施后调整回购股份价格上限的公告》。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关规定，公司在回购期间应当在每个月的前三个交易 日内披露截至上月末的回购进展情况。现将公司截至上月末的回购股份 ...

迪安诊断（ [Table_StockNameRptType] 300244） 公司点评 二季度收入环比改善，减值影响利润 | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company reported a revenue of 6.218 billion yuan for the first half of 2024, representing a year-over-year increase of 9.12%, while the net profit attributable to the parent company was 72 million yuan, a decrease of 84.17% year-over-year [1] - The company aims to position itself as a "provider of integrated medical diagnostic solutions" and has launched 176 new testing projects in the first half of 2024, with diagnostic service revenue reaching 2.362 billion yuan [1] - The company's ICL business showed steady growth, with revenue of 2.188 billion yuan, an increase of 6.32% year-over-year [1] - The special inspection business revenue reached 961 million yuan, accounting for 40.69% of the diagnostic service revenue, an increase of 1.19 percentage points from the end of 2023 [1] - The company is accelerating its digital transformation to enhance operational efficiency, with significant improvements in laboratory automation and AI-driven testing capabilities [1] Financial Summary - The company expects revenues for 2024-2026 to be 13.275 billion, 14.444 billion, and 15.779 billion yuan, with year-over-year growth rates of -1.0%, 8.8%, and 9.2% respectively [2] - The net profit attributable to the parent company is projected to be 439 million, 701 million, and 926 million yuan for 2024-2026, with year-over-year growth rates of 42.9%, 59.7%, and 32.0% respectively [2] - The gross margin is expected to be 29.2%, 31.0%, and 32.9% for 2024-2026 [2] - The company's P/E ratios are projected to be 15.05, 9.43, and 7.14 for 2024-2026 [2]

多重扰动下常规 ICL 增长稳健，看好下半年政策缓和下业绩回升 迪安诊断（300244）/医疗器械 证券研究报告/公司点评 2024 年 8 月 26 日 [Table_Industry] | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Recommended" rating for the company [3][4]. Core Views - The company reported a revenue of 6.218 billion yuan for the first half of 2024, a decrease of 9.12% year-on-year, and a net profit attributable to shareholders of 72 million yuan, down 84.17% [2]. - The core business performance is expected to stabilize in the second half of the year, despite short-term fluctuations due to industry restructuring and competition [2]. - The company has been enhancing operational efficiency through digitalization and AI-driven processes, which is expected to improve service delivery [2]. Summary by Sections Financial Performance - For H1 2024, the company experienced a decline in diagnostic services and products, with revenues of 2.362 billion yuan from diagnostic services (down 13.40%) and 4.085 billion yuan from diagnostic products (down 5.94%) [2]. - The company incurred credit impairment losses of 255 million yuan, significantly impacting apparent profits, primarily due to extended aging of accounts receivable [2]. - The revenue structure shows that the ICL segment grew by 6.32% year-on-year, while the special inspection business generated 961 million yuan, accounting for 40.69% of the diagnostic services revenue [2]. Future Outlook - The company anticipates a significant improvement in apparent growth rates in the second half of 2024, driven by a lower base effect and recovery in hospital testing volumes [3]. - The net profit forecasts for 2024-2026 are adjusted to 587 million, 726 million, and 883 million yuan, representing year-on-year growth rates of 90.87%, 23.76%, and 21.62% respectively [3][8]. - The expected earnings per share (EPS) for the same period are projected to be 0.94, 1.16, and 1.41 yuan, with corresponding price-to-earnings (PE) ratios of 11, 9, and 7 times [3][8].

证券代码：300244 证券简称：迪安诊断 公告编号：2024-068 迪安诊断技术集团股份有限公司 关于 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等相关规定，迪安诊断技术集团 股份有限公司（以下简称"公司"）就 2024 年半年度募集资金存放与使用情况作 如下专项报告： 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额及资金到账时间 经中国证券监督管理委员会证监许可【2018】1314 号文核准，公司向特定 对象非公开发行新增股份 69,428,843.00 股，发行价格每股 15.48 元（货币单位为 人民币，下同），募集资金总额为 1,074,758,489.64 元，扣除发行费用 12,782,480.04 元，实际募集资金净额为人民币 1,061,976,009.60 元。上述募集资金已于 ...

关于 2024 年中期利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）于 2024 年 8 月 22 日召 开第五届董事会第九次会议、第五届监事会第六次会议，审议通过了《关于 2024 中期利润分配预案的议案》，本议案尚需提交公司 2024 年第四次临时股东大会审 议。现将具体情况公告如下： 一、2024年中期利润分配预案基本情况 公司 2024 年半年度合并会计报表实现归属于上市公司股东的净利润 71,746,812.52 元，其中母公司实现净利润 35,799,124.26 元。根据《公司法》等 有关法律法规及《公司章程》的规定提取法定盈余公积后，截至 2024 年 6 月 30 日，公司合并报表累计未分配利润为 4,878,338,970.55 元，母公司累计未分配利 润为 1,785,303,036.64 元。 证券代码：300244 证券简称：迪安诊断 公告编号：2024-069 迪安诊断技术集团股份有限公司 根据相关法律法规及《公司章程》的规定，并结合公司实际经营状况和充分 考虑未 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥6,218,158,526.59, a decrease of 9.12% compared to the same period last year[11]. - Net profit attributable to shareholders was ¥71,746,812.52, down 84.17% year-on-year[11]. - The net cash flow from operating activities was negative at ¥-278,924,538.91, a decline of 1,101.44% compared to the previous year[11]. - The company's operating revenue for the reporting period was approximately ¥6.22 billion, a decrease of 9.12% compared to the previous year[44]. - The company's operating costs were approximately ¥4.50 billion, down by 1.70% year-on-year[44]. - The company's R&D investment decreased by 29.89% to approximately ¥154.76 million compared to the previous year[44]. - The company achieved a gross margin of 32.39% in the service sector, down by 10.93% year-on-year[45]. - The company reported a net profit margin of 15% for the first half of 2023, up from 10% in the same period last year, indicating improved operational efficiency[94]. Market Position and Strategy - The company is actively expanding its market presence and exploring potential mergers and acquisitions[4]. - The company is focusing on five strategic priorities, including deepening precision centers and collaborative construction, and expanding international markets through a "service + product" model[26]. - The company is committed to enhancing its core competitiveness and sustainable development capabilities through model and technology innovation[68]. - The company is exploring potential mergers and acquisitions to further strengthen its market position and expand its service offerings[93]. - The company is focusing on expanding its market presence, with multiple contracts signed for medical testing services, indicating a strong demand in the sector[93]. Risk Management - The company emphasizes the importance of risk management and has detailed potential risks in the report[1]. - The company aims to enhance its management level and organizational structure to mitigate management risks associated with rapid expansion[67]. - The company is strengthening accounts receivable management to reduce the risk of bad debts amid increasing competition and extended customer settlement cycles[70]. Quality Control and Compliance - The company is committed to a comprehensive quality management strategy to ensure sustainable business development amid ongoing anti-corruption efforts in the healthcare sector[24]. - The company emphasizes the importance of quality control in diagnostic services to maintain its competitive edge and brand image[66]. - The company is committed to a "zero defect" quality management principle to enhance the quality of its diagnostic services throughout the entire lifecycle[66]. Research and Development - The company launched 176 new testing projects during the reporting period[29]. - The company added 25 invention patents and 52 utility model patents during the reporting period, with 124 invention patents currently under application[35]. - The company is pursuing market expansion strategies, targeting a 30% increase in market share by the end of 2024 through strategic partnerships and acquisitions[95]. - The company has established a new research center aimed at developing innovative diagnostic technologies, with an expected completion date in early 2025[95]. Financial Position - The total assets at the end of the reporting period were ¥17,546,997,257.65, a decrease of 2.19% from the end of the previous year[11]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,778,093,501.48, representing 10.13% of total assets, a decrease of 6.44% compared to the previous year[46]. - Accounts receivable reached ¥8,566,708,588.77, accounting for 48.82% of total assets, an increase of 3.92% year-over-year[46]. - The total liabilities decreased to CNY 7,713,805,747.11 from CNY 8,034,531,783.60, a reduction of approximately 4%[118]. Shareholder Information - The company reported a cash dividend of 6.5 RMB per 10 shares, based on a total of 611,573,436 shares[1]. - The total distributable profit for the company was 1,785,303,036.64 RMB, with the cash dividend accounting for 100% of the profit distribution[76]. - The company plans to repurchase shares using a total amount of no less than RMB 100 million and no more than RMB 200 million, with a total of 10,344,100 shares repurchased, accounting for 1.65% of the total share capital as of June 30, 2024[101]. Operational Efficiency - The company aims to enhance operational efficiency and reduce costs through deep cooperation and precise center models[18]. - The digital transaction system improved business process efficiency by 25%, financial analysis efficiency by 70%, and supply chain operation efficiency by 90%[28]. - The company plans to upgrade its information systems to achieve standardized processes and intelligent decision-making through full digital management[67]. Legal and Regulatory Compliance - The company reported no significant environmental penalties during the reporting period, adhering to national environmental protection laws[78]. - There were no major litigation or arbitration matters reported during the period, indicating a stable legal environment for the company[80]. - The company did not engage in any significant related-party transactions during the reporting period, ensuring transparency in financial dealings[82]. Future Outlook - The company anticipates a growth rate of approximately 5% in its service contracts over the next year, reflecting a positive market outlook[93]. - Future guidance suggests a continued upward trend in revenue, with expectations of reaching 1,000 million in contracts by the end of 2023[97]. - The overall performance in the first half of 2024 shows a robust growth trajectory, with a clear strategy for sustaining this momentum in the coming quarters[97].

证券代码：300244 证券简称：迪安诊断 公告编号：2024-070 迪安诊断技术集团股份有限公司 关于召开 2024 年第四次临时股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）定于 2024 年 9 月 9 日（星期一）14 点 30 分召开 2024 年第四次临时股东大会，本次会议采取现场 表决与网络投票相结合的方式召开，现将有关事项通知如下： 一、召开会议的基本情况 1、会议届次：2024 年第四次临时股东大会 2、会议召集人：公司董事会 公司于 2024 年 8 月 22 日召开的第五届董事会第九次会议审议通过了《关于 召开 2024 年第四次临时股东大会的议案》。 3、会议召开的合法、合规性： 6、股权登记日：2024 年 9 月 3 日（星期二） 7、出席对象： 本次会议议案已经公司第五届董事会第九次会议、第五届监事会第六次会议 审议通过；本次股东大会会议的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》的有关规定。 4、会议召开的日期和时间 （1）现场会议时间 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2024-065 迪安诊断技术集团股份有限公司 第五届董事会第九次会议决议公告 二、 《关于<2024 年半年度募集资金存放与使用情况的专项报告>的议案》 2024 年 1-6 月，公司按照相关法律、法规以及规范性文件的规定和要求存 放并使用募集资金，并对募集资金的存放、使用情况进行了及时的披露。 具体内容详见公司在巨潮资讯网披露的《关于 2024 年半年度募集资金存放 与使用情况的专项报告》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 三、 《关于 2024 年中期利润分配预案的议案》 在保证公司正常经营和长远发展的前提下，为了更好的兼顾股东的即期利 益和长远利益，2024 年中期利润分配预案为：以权益分派方案实施时股权登记 日的总股本，扣除公司通过集中竞价交易方式回购股份后的股本为基数，向全体 股东每 10 股派发现金红利 6.5 元（含税），不送红股，不以资本公积金转增股本。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 8 月 22 日上午 9 点，迪安诊断技术集团股份有 ...